Evaluation of the Depth and Duration of Anesthesia From Heated Lidocaine/Tetracaine (Synera®) Patches Compared With 5% Lidocaine (Lidoderm®) Patches Applied to Healthy Adult Volunteers



Status:Completed
Conditions:Healthy Studies
Therapuetic Areas:Other
Healthy:No
Age Range:Any
Updated:11/18/2012
Start Date:September 2012
End Date:October 2012
Contact:Cher Struck
Email:cstruck@crilifetree.com
Phone:801-269-8200

Use our guide to learn which trials are right for you!


This will be a randomized, single-blind, active-controlled, two-period crossover study in
adult volunteers to compare the duration and depth of anesthesia between Synera® and
Lidoderm® patches when applied for 30 minutes and 4 hours. The study will include a
Screening Visit, two Treatment Periods, and a Follow-Up Phone Contact.


Inclusion:

1. Subject is male or female 18-60 years of age, inclusive.

2. Subject is judged by the Investigator to be in generally good health at screening
based upon the results of a medical history, physical examination, clinical
laboratory profile, and 12-lead electrocardiogram (ECG).

3. Subject is willing to refrain from using any local topical preparations on the volar
aspect of the forearms for 24 hours prior to each site visit.

4. Subject has normal, intact skin bilaterally at the antecubital area.

5. If female, must be of non-childbearing potential (defined as postmenopausal for at
least 1 year or surgically sterile [bilateral tubal ligation, bilateral oophorectomy
or hysterectomy]) or must be using adequate contraception (practicing one of the
following methods of birth control):

- Total abstinence from sexual intercourse (minimum of one complete menstrual
cycle before study entry),

- A vasectomized partner,

- Contraceptives (oral, parenteral, or transdermal) for 3 consecutive months prior
to test product administration,

- Intrauterine device (IUD), or

- Double-barrier method (condoms, sponge, diaphragm, or vaginal ring with
spermicidal jellies or cream).

6. If female, must have a negative urine pregnancy test at Screening and at check-in of
each Treatment Period.

7. Subject is willing to be blindfolded during the study and agrees to abide by all
study restrictions and comply with all study procedures.

8. Able to fluently speak and understand English and be able to provide meaningful
written informed consent for the study.

Exclusion:

1. Subject has clinically significant ECG abnormalities at screening.

2. Subject is currently receiving class I, II, or III anti-arrhythmic agents.

3. Subject has used over-the-counter (OTC) or prescription analgesics within 24 hours
prior to either study period.

4. Subject has a known allergy or history of significant adverse reaction to any
component of the treatment or related compounds.

5. Subject has a history of or active use or abuse of illicit drug substance or alcohol
abuse.

6. Subject has a positive urine test result for drugs of abuse or a positive ethanol
breath test at the Screening Visit or check-in to Treatment Visit 1.

7. Subject has active dermatological disease of any origin that may interfere with the
ability to participate.

8. Subject has denuded or broken skin on either forearm.

9. Subject has a history of unstable peripheral/vascular disease and/or hypertensive
vascular disease.
We found this trial at
1
site
3838 South 700 East
Salt Lake City, Utah 84106
801-269-8200
?
mi
from
Salt Lake City, UT
Click here to add this to my saved trials